Troels Koch, PhD

Senior Vice President, Chemistry at MiNa Therapeutics

Speaker

Troels Koch (TK) currently CTO & Head of Chemistry in MiNA Therapeutics. TK is a founder of several biotech companies e.g. Exiqon and Santaris Pharma. Santaris Pharma was acquired by Roche in 2014. As VP and CTO in Santaris Pharma and in Roche TK was leading chemistry and platform research. TK pioneered LNA therapeutics and has positioned LNA antisense science and technology at an international lead position. TK has worked with RNA therapeutics for 20+ years and taken an active role in all steps of oligonucleotide drug discovery and development and advanced 7 LNAs into clinical trials. TK has built R&D organizations up to 75 FTEs, held >100 invited presentations at international conferences and is author of 90 peer reviewed publications. TK has been positioned in company management teams and taken part in all aspects of executive decision making company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D.